Ulf Petrausch
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. J Clin Oncol 2023; 41:5131-5139.
Aug 17, 2023Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Aug 17, 2023J Clin Oncol 2023; 41:5131-5139
Cathomas Richard, Rothschild Sacha I, Hayoz Stefanie, Bubendorf Lukas, Özdemir Berna C, Kiss Bernhard, Erdmann Andreas, Aeppli Stefanie, Mach Nicolas, Strebel Räto T, Hadaschik Boris, Berthold Dominik R, John Hubert, Zihler Deborah, Schmid Mathias, Alborelli Ilaria, Schneider Martina, Musilova Jana, Spahn Martin, Petrausch Ulf
Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrausch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol 2018
Aug 21, 2018Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Aug 21, 2018J Thorac Oncol 2018
Metaxas Yannis, Froesch Patrizia, Löffler-Baumann Melanie, Pratsch-Peter Susanne, Russell Prudence, Mingrone Walter, Savic Spasenija, Thapa Bibhusal, Früh Martin, Pless Miklos, von Moos Roger, Mauti Laetitia, O'Byrne Kenneth, Petrausch Ulf, Wolleb Sybille, Rivalland Gareth, Klingbiel Dirk, Kao Steven, Schmid Sabine, Nowak Anna K, Gautschi Oliver, Bartnick Tammo, Hughes Brett G, Bouchaab Hasna, Rothschild Sacha, Pavlakis Nick, John Thomas
Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome
Sönnichsen A, Cozzio A, Hoetzenecker W, Schmid-Grendelmeier P, Petrausch U, Chang Y, Desislava I, Mehra T, Kerl K, Mangana J, Saulite I, Guenova E. Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome. J Dermatolog Treat 2016; 27:436-8.
Feb 10, 2016Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome
Feb 10, 2016J Dermatolog Treat 2016; 27:436-8
Sönnichsen Astrid, Cozzio Antonio, Hoetzenecker Wolfram, Schmid-Grendelmeier Peter, Petrausch Ulf, Chang Yun-Tsan, Desislava Ignatova, Mehra Tarun, Kerl Katrin, Mangana Johanna, Saulite Ieva, Guenova Emmanuella
Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
Samaras P, Renner C, Stahel R, Knuth A, Taverna C, Schäfer N, Mischo A, Schanz U, Siciliano R, Honegger H, Haile S, Buset E, Petrausch U, Zardavas D, Stenner-Liewen F. Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. Swiss Med Wkly 2013; 143:w13791.
May 7, 2013Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation
May 7, 2013Swiss Med Wkly 2013; 143:w13791
Samaras Panagiotis, Renner Christoph, Stahel Rolf, Knuth Alexander, Taverna Christian, Schäfer Niklaus G, Mischo Axel, Schanz Urs, Siciliano Raffaele D, Honegger Hanspeter, Haile Sarah, Buset Elefteri M, Petrausch Ulf, Zardavas Dimitrios, Stenner-Liewen Frank
Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience
Samaras P, Stenner-Liewen F, Knuth A, Bauer S, Taverna C, Stussi G, Schanz U, Honegger H, Zweifel M, Mischo A, Petrausch U, Siciliano R, Haile S, Blickenstorfer M, Renner C. Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. Swiss Med Wkly 2011; 141:w13203.
May 31, 2011Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience
May 31, 2011Swiss Med Wkly 2011; 141:w13203
Samaras Panagiotis, Stenner-Liewen Frank, Knuth Alexander, Bauer Stefan, Taverna Christian, Stussi Georg, Schanz Urs, Honegger Hanspeter, Zweifel Martin, Mischo Axel, Petrausch Ulf, Siciliano Raffaele Daniele, Haile Sarah, Blickenstorfer Marcel, Renner Christoph
Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation
Samaras P, Renner C, Knuth A, Stahel R, Stussi G, Schanz U, Pestalozzi B, Honegger H, Mischo A, Petrausch U, Haile S, Siciliano R, Buset E, Stenner-Liewen F. Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation. Oncology 2010; 79:93-97.
Nov 15, 2010Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation
Nov 15, 2010Oncology 2010; 79:93-97
Samaras Panagiotis, Renner Christoph, Knuth Alexander, Stahel Rolf A, Stussi Georg, Schanz Urs, Pestalozzi Bernhard C, Honegger Hanspeter, Mischo Axel, Petrausch Ulf, Haile Sarah, Siciliano Raffaele Daniele, Buset Elefteri M, Stenner-Liewen Frank
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
Samaras P, Stenner-Liewen F, Knuth A, Stahel R, Stussi G, Schanz U, Honegger H, Mischo A, Petrausch U, Buset E, Haile S, Siciliano R, Blickenstorfer M, Renner C. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann Hematol 2010; 90:89-94.
Aug 13, 2010Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim
Aug 13, 2010Ann Hematol 2010; 90:89-94
Samaras Panagiotis, Stenner-Liewen Frank, Knuth Alexander, Stahel Rolf A, Stussi Georg, Schanz Urs, Honegger Hanspeter, Mischo Axel, Petrausch Ulf, Buset Elefteri M, Haile Sarah, Siciliano Raffaele Daniele, Blickenstorfer Marcel, Renner Christoph
Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP
Samaras P, Stenner-Liewen F, Knuth A, Zweifel M, Mischo A, Meisel A, Siciliano R, Schaefer N, Petrausch U, Haile S, Heider H, Renner C. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 2010; 89:783-7.
Mar 5, 2010Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP
Mar 5, 2010Ann Hematol 2010; 89:783-7
Samaras Panagiotis, Stenner-Liewen Frank, Knuth Alexander, Zweifel Martin, Mischo Axel, Meisel Alexander, Siciliano Raffaele Daniele, Schaefer Niklaus G, Petrausch Ulf, Haile Sarah, Heider Helen, Renner Christoph